HMO and EPO insurance plans are more likely to promote the use of biosimilars
This article originally appeared on HCPLive®. Patients with low-flexibility plans, such as exclusive provider organizations (EPOs) and health maintenance organizations (HMOs), were more likely to include patients who started biosimilars …